FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry. Variants of humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof may be administered to a subject without an unacceptable increase of proinflammatory cytokines. Antibodies or fragments thereof are used in methods of treating diseases and conditions mediated by increased levels or activity of IL-10, such as systemic lupus erythematosus.
EFFECT: invention makes it possible to cause a smaller increase in pro-inflammatory cytokines.
30 cl, 21 dwg, 10 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTI-IL-10 ANTIBODIES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | 2010 |
|
RU2587622C2 |
| METHOD OF TREATING AUTOIMMUNE DISEASE (VERSIONS) | 2009 |
|
RU2539110C2 |
| AGENT FOR TREATING DISEASE | 2009 |
|
RU2540013C2 |
| COMBINATION OF ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND MOLECULE BINDING TO B-CELLS, B-CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART | 2008 |
|
RU2484845C2 |
| AGENT FOR DISEASE TREATMENT | 2009 |
|
RU2540018C2 |
| IL-31 MONOCLONAL ANTIBODIES AND METHODS OF USING | 2006 |
|
RU2444528C2 |
| DRUGS FOR TREATING DISEASES | 2010 |
|
RU2598719C2 |
| BINDING RGMA PROTEIN AND USE THEREOF | 2016 |
|
RU2705304C2 |
| IMMUNOGLOBULINS K HUMAN CD52 | 2010 |
|
RU2603743C2 |
| THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
